Latest Options News

Thor Energy has agreed to sell its 75% stake in the FRAM Joint Venture to Tivan Limited for A$8.75 million, significantly strengthening its balance sheet and accelerating its focus on natural hydrogen and helium exploration in South Australia.

Investigator Resources has agreed to sell its 25% stake in the Molyhil tungsten-molybdenum project to Tivan Limited, unlocking over A$3 million in value and sharpening its focus on precious metals development.

Core Energy Minerals has confirmed uranium mineralisation at its Cummins Project in South Australia through a maiden aircore drilling program, reinforcing its geological model and setting the stage for targeted follow-up exploration.

Next Science has finalised the sale of nearly all its assets to OSARTIS GmbH for US$50 million, with plans to return approximately US$30 million net proceeds to shareholders following legal and tax review.

New Hope Group’s FY25 results reveal a robust increase in coal production and improved safety, alongside steady shareholder dividends and strategic capital management.

New Hope Corporation reported an 18.1% rise in coal production for FY25 alongside an 8.4% reduction in unit costs, declaring a fully franked 15-cent dividend and launching a Dividend Reinvestment Plan.

New Hope Corporation Limited has unveiled a Dividend Reinvestment Plan (DRP) offering eligible Australian and New Zealand shareholders a flexible, fee-free way to reinvest dividends into additional shares. The plan empowers investors to grow their holdings conveniently while maintaining control over participation levels.

New Hope Corporation Limited has announced a fully franked final dividend of AUD 0.15 per share for FY2025, with a Dividend Reinvestment Plan available to shareholders.

New Hope Corporation Limited posted a slight dip in revenue and net profit for FY2025 but achieved a notable 18% rise in saleable coal production, driven by growth at New Acland Mine and steady output at Bengalla Mine.

CSL Limited has partnered with Dutch biotech VarmX to develop VMX-C001, a novel treatment aimed at reversing bleeding in patients on FXa inhibitors, with FDA Fast Track status and a potential 2029 launch.

Metro Performance Glass has successfully closed an oversubscribed rights offer, raising $23.9 million to support its turnaround and growth strategy, with Amari Metals securing a 51% stake.

Oceania Healthcare has unveiled a comprehensive strategy focused on sales performance, operational excellence, and capital management to strengthen its aged care and retirement living portfolio. The company aims to reduce debt, enhance resident choice, and expand services while maintaining strong occupancy and shareholder returns.